{"protocolSection":{"identificationModule":{"nctId":"NCT05775289","orgStudyIdInfo":{"id":"BO44178"},"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer","officialTitle":"A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2025-11","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-03-15","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06-20","type":"ACTUAL"},"completionDateStruct":{"date":"2026-06-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-03-06","studyFirstSubmitQcDate":"2023-03-16","studyFirstPostDateStruct":{"date":"2023-03-20","type":"ACTUAL"},"resultsFirstSubmitDate":"2025-08-27","resultsFirstSubmitQcDate":"2025-11-11","resultsFirstPostDateStruct":{"date":"2025-11-19","type":"ESTIMATED"},"lastUpdateSubmitDate":"2025-11-11","lastUpdatePostDateStruct":{"date":"2025-11-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based chemotherapy compared with pembrolizumab plus platinum-based chemotherapy in participants with previously untreated, locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) non-small-cell lung cancer (NSCLC) who are not eligible to receive curative surgery and/or definitive chemoradiotherapy."},"conditionsModule":{"conditions":["Non-small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR"]}},"enrollmentInfo":{"count":182,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm A: Tobemstomig + Platinum-Based Chemotherapy","type":"EXPERIMENTAL","description":"Participants with non-squamous (NSQ) NSCLC will receive induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin, all on Day 1 every 3 weeks (Q3W) for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig together with pemetrexed until disease progression or treatment discontinuation.\n\nParticipants with squamous (SQ) NSCLC will receive blinded tobemstomig in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21 day cycles, followed by blinded tobemstomig (on Day 1) Q3W until disease progression or treatment discontinuation.","interventionNames":["Drug: Tobemstomig","Drug: Paclitaxel","Drug: Pemetrexed","Drug: Carboplatin"]},{"label":"Arm B: Pembrolizumab + Platinum-Based Chemotherapy","type":"ACTIVE_COMPARATOR","description":"Participants with NSQ NSCLC will receive induction treatment with blinded pembrolizumab in combination with pemetrexed and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by a maintenance therapy with blinded pembrolizumab together with pemetrexed Q3W until disease progression or treatment discontinuation.\n\nParticipants with SQ NSCLC will receive blinded pembrolizumab in combination with paclitaxel and carboplatin, all on Day 1 Q3W for four 21-day cycles, followed by blinded pembrolizumab (on Day 1) Q3W until disease progression or treatment discontinuation.","interventionNames":["Drug: Pembrolizumab","Drug: Paclitaxel","Drug: Pemetrexed","Drug: Carboplatin"]}],"interventions":[{"type":"DRUG","name":"Tobemstomig","description":"Participants will receive intravenous (IV) tobemstomig for four 21-day cycles","armGroupLabels":["Arm A: Tobemstomig + Platinum-Based Chemotherapy"],"otherNames":["RO7247669"]},{"type":"DRUG","name":"Pembrolizumab","description":"Participants will receive IV pembrolizumab four 21-day cycles","armGroupLabels":["Arm B: Pembrolizumab + Platinum-Based Chemotherapy"]},{"type":"DRUG","name":"Paclitaxel","description":"Participants will receive IV paclitaxel Q3W for four 21-day cycles","armGroupLabels":["Arm A: Tobemstomig + Platinum-Based Chemotherapy","Arm B: Pembrolizumab + Platinum-Based Chemotherapy"]},{"type":"DRUG","name":"Pemetrexed","description":"Participants will receive IV pemetrexed Q3W until disease progression or unacceptable toxicity","armGroupLabels":["Arm A: Tobemstomig + Platinum-Based Chemotherapy","Arm B: Pembrolizumab + Platinum-Based Chemotherapy"]},{"type":"DRUG","name":"Carboplatin","description":"Participants will receive IV carboplatin Q3W for four 21-day cycles","armGroupLabels":["Arm A: Tobemstomig + Platinum-Based Chemotherapy","Arm B: Pembrolizumab + Platinum-Based Chemotherapy"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS)","description":"PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.","timeFrame":"Randomization to date of first documented disease progression or death (up to approximately 15 months)"},{"measure":"Objective Response Rate (ORR)","description":"ORR is defined as the percentage of participants who experience a complete reponse or partial response on two consecutive occasions at least 4 weeks apart as determined by the investigator according to RECIST v1.1.","timeFrame":"Up to approximately 15 months"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization to death from any cause.","timeFrame":"From randomization to death from any cause (up to approximately 15 months)"},{"measure":"Duration of Response (DOR)","description":"DOR is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first.","timeFrame":"From the first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first) (up to approximately 15 months)"},{"measure":"PFS in Participants With PD-L1 Expression","timeFrame":"Up to 28 months"},{"measure":"OS for Participants With PD-L1 Expression","timeFrame":"Up to 28 months"},{"measure":"Change in Participant-reported Outcomes as Assessed by the European Organisation for Research and Treatment (EORTC): Physical Functioning","description":"The EORTC Item Library 17 (IL17) physical functioning scale measures a participant's ability to perform a variety of physical activities. Raw scores are calculated by estimating the average of the items that contribute to the scale. Linear transformation is then used to standardize the raw score to a total score range of 0-100. Higher scores for this measure indicate better outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Global Health Status/Quality of Life (GHS/QoL)","description":"The EORTC Item Library 17 (IL17) Global Health Status/Quality of Life (GHS/QoL) scale measures the participant's overall health and quality of health over the last week. Raw scores are calculated by estimating the average of the items that contribute to the scale. Linear transformation is then used to standardize the raw score to a total score range of 0-100. Higher scores for this measure indicate a higher quality of life.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Role Functioning","description":"The EORTC Item Library 17 (IL17) role functioning scale measures the degree to which disease or treatment interferes with the participant's work or daily activities. Raw scores are calculated by estimating the average of the items that contribute to the scale. Linear transformation is then used to standardize the raw score to a total score range of 0-100. Higher scores for this measure indicate better outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Lung Cancer Symptoms/How Much Did You Cough","description":"The EORTC IL 85 lung cancer symptoms/how much did you cough measure assesses the severity and frequency of coughing over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath When Rested","description":"The EORTC IL 85 short of breath when rested measure assesses the degree of difficulty breathing while resting over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath When Walked","description":"The EORTC IL 85 short of breath when walked measure assesses the degree of difficulty breathing while walking over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath Climbed Stairs","description":"The EORTC IL 85 short of breath climbed stairs measure assesses the degree of difficulty breathing while climbing stairs over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Pain in Chest","description":"The EORTC IL 85 pain in chest measure assesses the severity of chest pain over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Need to Rest","description":"The EORTC IL 132 need to rest measure assesses how often the participant felt the need to rest over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Felt Weak","description":"The EORTC IL 132 felt weak measure assesses how often the participant felt weak over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Tired","description":"The EORTC IL 132 tired measure assesses how often the participant felt tired over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Change in Participant-reported Outcomes as Assessed by the EORTC: Aches/Pain in Bones","description":"The EORTC IL 188 aches/pain in bones measure assessesthe severity of bone pain over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","timeFrame":"Baseline to week 12"},{"measure":"Number of Participants With Adverse Events (AEs)","timeFrame":"From the start of treatment to 90 days after the final dose of treatment (up to 28 months)"},{"measure":"Maximum Serum Concentration (Cmax) of Tobemstomig","timeFrame":"Up to approximately 15 months"},{"measure":"Time of Maximum Concentration (Tmax) of Tobemstomig","timeFrame":"Up to approximately 15 months"},{"measure":"Clearance (CL) of Tobemstomig","timeFrame":"Up to approximately 15 months"},{"measure":"Volume of Distribution at Steady State (Vss) of Tobemstomig","timeFrame":"Up to approximately 15 months"},{"measure":"Area Under the Concentration-time Curve (AUC) of Tobemstomig","timeFrame":"Up to approximately 15 months"},{"measure":"Half-life (T1/2) of Tobemstomig","timeFrame":"Up to approximately 15 months"},{"measure":"Percentage of Participants With Anti-drug Antibodies (ADAs)","timeFrame":"Baseline up to approximately 15 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Histologically or cytologically documented locally advanced, unresectable (Stage IIIB/IIIC) or metastatic (Stage IV) NSCLC who are not eligible for curative surgery and/or definitive chemoradiotherapy\n* No prior systemic treatment for metastatic NSCLC\n* Known tumor PD-L1 status\n* Confirmed availability of representative tumor specimens\n* Measurable disease\n* Life expectancy of at least 12 weeks\n* Adequate hematologic and end-organ function\n* Negative for HIV, hepatitis B (HBV), and hepatitis C (HCV)\n* Adequate cardiovascular function\n\nExclusion Criteria:\n\n* NSCLC known to have a mutation in the EGFR gene or an ALK fusion oncogene\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Untreated or clinically unstable spinal cord confession\n* History of leptomeningeal disease\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once a month or more frequently)\n* Uncontrolled or symptomatic hypercalcemia\n* Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, granulomatosis with polyangiitis, Sjögren syndrome, Guillain-Barré syndrome, or multiple sclerosis, with exceptions defined by the protocol\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on the screening chest computed tomography (CT) scan\n* Active tuberculosis (TB) or untreated latent TB\n* Current treatment with anti-viral therapy for HBV or HCV\n* Significant cardiovascular disease within 3 months prior to randomization\n* Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study\n* History of malignancy other than NSCLC within 5 years prior to randomization, with the exception of malignancies with a negligible risk of metastasis or death e.g., 5-year OS\\] rate \\> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer\n* Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia, or any active infection that could affect patient safety\n* Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment\n* Prior allogeneic stem cell or solid organ transplantation\n* Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications\n* Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during study treatment or within 5 months after the final dose of study treatment\n* Treatment with investigational therapy within 28 days prior to initiation of study treatment\n* Any anti-cancer therapy, including hormonal therapy, within 21 days prior to initiation of study treatment\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including, but not limited to, anti-cytotoxic T lymphocyte-associated protein 4, anti-T cell immunoreceptor with Ig and tyrosine-based inhibition motif domains, anti-PD-1 and anti-PD-L1 therapeutic antibodies, and anti-LAG3) agents\n* Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2) within 4 weeks or 5 drug-elimination half lives (whichever is longer) prior to initiation of study treatment\n* Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[TNF\\] agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment\n* History of severe allergic anaphylactic reactions to chimeric or humanized antibodies, fusion proteins, or platinum-containing compounds\n* Known hypersensitivity to Chinese hamster ovary cell products or to any component of the tobemstomig or pembrolizumab formulation\n* Known allergy or hypersensitivity or other contraindication to any component of the chemotherapy regimen the patient may receive during the study\n* Pregnancy or breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-LaRoche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Henry Ford Health System","city":"Detroit","state":"Michigan","zip":"48202-2689","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Renown Regional Medical Center Hospital","city":"Reno","state":"Nevada","zip":"89502-1576","country":"United States","geoPoint":{"lat":39.52963,"lon":-119.8138}},{"facility":"Westmead Hospital","city":"Westmead","state":"New South Wales","zip":"2145","country":"Australia","geoPoint":{"lat":-33.80383,"lon":150.98768}},{"facility":"Lyell McEwin Hospital","city":"Adelaide","state":"South Australia","zip":"5112","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Barwon Health","city":"Geelong","state":"Victoria","zip":"3220","country":"Australia","geoPoint":{"lat":-38.14711,"lon":144.36069}},{"facility":"Monash Health","city":"Melbourne","state":"Victoria","zip":"3168","country":"Australia","geoPoint":{"lat":-37.814,"lon":144.96332}},{"facility":"UZ Brussel","city":"Brussels","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Jessa Zkh (Campus Virga Jesse)","city":"Hasselt","zip":"3500","country":"Belgium","geoPoint":{"lat":50.93106,"lon":5.33781}},{"facility":"UZ Leuven Gasthuisberg","city":"Leuven","zip":"3000","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"AZ St Maarten Campus Leopoldstr","city":"Mechelen","zip":"2800","country":"Belgium","geoPoint":{"lat":51.02574,"lon":4.47762}},{"facility":"Crio - Centro Regional Integrado de Oncologia","city":"Fortaleza","state":"Ceará","zip":"60336-550","country":"Brazil","geoPoint":{"lat":-3.71722,"lon":-38.54306}},{"facility":"Nucleo de Oncologia da Bahia - NOB","city":"Salvador, Bahia","state":"Estado de Bahia","zip":"40170-380","country":"Brazil"},{"facility":"Hospital Nossa Senhora da Conceicao","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital de Clínicas de Porto Alegre X","city":"Porto Alegre","state":"Rio Grande do Sul","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"Hospital de Cancer de Barretos","city":"Barretos","state":"São Paulo","zip":"14784-400","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"Instituto do Cancer do Estado de Sao Paulo - ICESP","city":"São Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Centre Leon Berard","city":"Lyon","zip":"69008","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Hopital Cochin","city":"Paris","zip":"75679","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Ico Rene Gauducheau","city":"Saint-Herblain","zip":"44805","country":"France","geoPoint":{"lat":47.21154,"lon":-1.651}},{"facility":"CHU de Toulouse - Hôpital Larrey","city":"Toulouse","zip":"31100","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Uniklinik Essen","city":"Essen","zip":"45122","country":"Germany","geoPoint":{"lat":51.45657,"lon":7.01228}},{"facility":"LungenClinic Großhansdorf GmbH","city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"facility":"Krankenhaus Martha-Maria Halle-Doelau","city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"facility":"Thoraxklinik Heidelberg gGmbH","city":"Heidelberg","zip":"69126","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Lungenfachklinik Immenhausen","city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"facility":"Azienda Ospedaliera San Giuseppe Moscati","city":"Avellino","state":"Campania","zip":"83100","country":"Italy","geoPoint":{"lat":40.91494,"lon":14.79103}},{"facility":"AZ.Osp S. Orsola ? Malpighi-Reparto di Oncologia Medica","city":"Bologna","state":"Emilia-Romagna","zip":"40138","country":"Italy","geoPoint":{"lat":44.49381,"lon":11.33875}},{"facility":"Policlinico Universitario \"Agostino Gemelli\"","city":"Rome","state":"Lazio","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"IRCCS AOU San Martino - IST","city":"Genoa","state":"Liguria","zip":"16132","country":"Italy","geoPoint":{"lat":44.40478,"lon":8.94439}},{"facility":"Irccs Istituto Europeo di Oncologia (IEO)","city":"Milan","state":"Lombardy","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Asst Di Monza","city":"Monza","state":"Lombardy","zip":"20900","country":"Italy","geoPoint":{"lat":45.58005,"lon":9.27246}},{"facility":"IOV - Istituto Oncologico Veneto - IRCCS","city":"Padua","state":"Veneto","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"facility":"ONCARE Viaducto Napoles","city":"Mexico City","state":"Mexico CITY (federal District)","zip":"03810","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"AMIISTO Atencion Medica Integral Investigacion y Terapia Oncologica S.A de C.V","city":"Mexico City","state":"Mexico CITY (federal District)","zip":"07300","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Instituto Nacional de Cancerologia","city":"Distrito Federal","zip":"14080","country":"Mexico","geoPoint":{"lat":16.59,"lon":-93.02694}},{"facility":"Pusan National University Hospital","city":"Busan","zip":"49241","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Severance Hospital, Yonsei University Health System","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Korea University Guro Hospital","city":"Seoul","zip":"08308","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital Son Llatzer","city":"Palma de Mallorca","state":"Balearic Islands","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"facility":"Institut Catala d Oncologia Hospitalet","city":"L'Hospitalet de Llobregat","state":"Barcelona","zip":"08908","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"Complejo Hospitalario Universitario A Coruña (CHUAC)","city":"A Coruña","state":"LA Coruna","zip":"15006","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"Hospital Universitari Vall d'Hebron","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario 12 de Octubre","city":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Regional Universitario Carlos Haya","city":"Málaga","zip":"29011","country":"Spain","geoPoint":{"lat":36.72016,"lon":-4.42034}},{"facility":"Memorial Ankara Hastanesi","city":"Ankara","zip":"06520","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Ankara City Hospital","city":"Ankara","zip":"06800","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi","city":"Edirne","zip":"22030","country":"Turkey (Türkiye)","geoPoint":{"lat":41.67719,"lon":26.55597}},{"facility":"Medipol University Medical Faculty","city":"Istanbul","zip":"34214","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"?zmir Medical Park","city":"Izm?r","zip":"35575","country":"Turkey (Türkiye)"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\\_sharing"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Male and female participants ages at least 18 years with previously untreated locally advanced or metastatic non-small cell lung cancer.","groups":[{"id":"FG000","title":"Pembro + Chemotherapy (Squamous)","description":"Participants with squamous non small-cell lung cancer (NSCLC) received blinded pembrolizumab (pembro) in combination with paclitaxel and carboplatin on Day 1 every three weeks (Q3W) for four 21-day cycles, followed by blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"FG001","title":"Pembro + Chemotherapy (Non-squamous)","description":"Participants with non-squamous (NSQ) NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"FG002","title":"Tobe + Chemotherapy (Squamous)","description":"Participants with SQ NSCLC received blinded tobemstomig in combination with paclitaxel and carboplatin on Day 1 Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"FG003","title":"Tobe + Chemotherapy (Non-squamous)","description":"Participants with NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"66"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"67"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"66"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"67"}]}],"dropWithdraws":[{"type":"Study Ongoing","reasons":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"53"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"55"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"11"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"12"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Progressive Disease","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pembro + Chemotherapy (Squamous)","description":"Participants with squamous non small-cell lung cancer (NSCLC) received blinded pembrolizumab (pembro) in combination with paclitaxel and carboplatin on Day 1 every three weeks (Q3W) for four 21-day cycles, followed by blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"BG001","title":"Pembro + Chemotherapy (Non-squamous)","description":"Participants with non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"BG002","title":"Tobe + Chemotherapy (Squamous)","description":"Participants with SQ NSCLC received blinded tobemstomig in combination with paclitaxel and carboplatin on Day 1 Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"BG003","title":"Tobe + Chemotherapy (Non-squamous)","description":"Participants with NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"67"},{"groupId":"BG004","value":"182"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66.2","spread":"6.8"},{"groupId":"BG001","value":"63.2","spread":"9.6"},{"groupId":"BG002","value":"63.0","spread":"11.2"},{"groupId":"BG003","value":"64.8","spread":"8.3"},{"groupId":"BG004","value":"64.2","spread":"9.0"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"64"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"43"},{"groupId":"BG004","value":"118"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"29"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"137"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"16"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"3"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"22"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"5"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"19"},{"groupId":"BG003","value":"53"},{"groupId":"BG004","value":"130"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"20"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS)","description":"PFS is defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.","populationDescription":"The analysis population included all participants that were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Randomization to date of first documented disease progression or death (up to approximately 15 months)","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.13","lowerLimit":"5.59","upperLimit":"NA","comment":"Value is NA due to insufficient number of participants with the event."},{"groupId":"OG001","value":"7.62","lowerLimit":"5.62","upperLimit":"NA","comment":"Value is NA due to insufficient number of participants with the event."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9705","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.99","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.63","ciUpperLimit":"1.56"}]},{"type":"PRIMARY","title":"Objective Response Rate (ORR)","description":"ORR is defined as the percentage of participants who experience a complete reponse or partial response on two consecutive occasions at least 4 weeks apart as determined by the investigator according to RECIST v1.1.","populationDescription":"The analysis population was all randomized participants with measurable disease at baseline.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percent of participants","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","lowerLimit":"36.28","upperLimit":"56.34"},{"groupId":"OG001","value":"41.1","lowerLimit":"31.51","upperLimit":"51.44"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4056","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Odds Ratio (OR)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.42","ciUpperLimit":"1.43"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization to death from any cause.","populationDescription":"The efficacy analysis population consisted of all participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From randomization to death from any cause (up to approximately 15 months)","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"13.37","upperLimit":"NA","comment":"Value is NA due to insufficient number of participants with the event."},{"groupId":"OG001","value":"13.17","lowerLimit":"12.02","upperLimit":"NA","comment":"Value is NA due to insufficient number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR)","description":"DOR is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first.","populationDescription":"The DOR analysis population consisted of participants who achieved an objective response to study treatment.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the first occurrence of a confirmed objective response to disease progression or death from any cause (whichever occurs first) (up to approximately 15 months)","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"37"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"9.7","upperLimit":"NA","comment":"Value is NA due to insufficient number of participants with the event."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Value is NA due to insufficient number of participants with the event."}]}]}]},{"type":"SECONDARY","title":"PFS in Participants With PD-L1 Expression","reportingStatus":"NOT_POSTED","timeFrame":"Up to 28 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"OS for Participants With PD-L1 Expression","reportingStatus":"NOT_POSTED","timeFrame":"Up to 28 months","denomUnitsSelected":"Participants"},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the European Organisation for Research and Treatment (EORTC): Physical Functioning","description":"The EORTC Item Library 17 (IL17) physical functioning scale measures a participant's ability to perform a variety of physical activities. Raw scores are calculated by estimating the average of the items that contribute to the scale. Linear transformation is then used to standardize the raw score to a total score range of 0-100. Higher scores for this measure indicate better outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.67","lowerLimit":"6.7","upperLimit":"100.0"},{"groupId":"OG001","value":"80.00","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"93.3","lowerLimit":"93.3","upperLimit":"93.3"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"80"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.00","lowerLimit":"20.0","upperLimit":"100.0"},{"groupId":"OG001","value":"80.00","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"80.00","lowerLimit":"20.0","upperLimit":"100.0"},{"groupId":"OG001","value":"80.00","lowerLimit":"20.0","upperLimit":"100.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"86.67","lowerLimit":"6.7","upperLimit":"100.0"},{"groupId":"OG001","value":"80.00","lowerLimit":"6.7","upperLimit":"100.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Global Health Status/Quality of Life (GHS/QoL)","description":"The EORTC Item Library 17 (IL17) Global Health Status/Quality of Life (GHS/QoL) scale measures the participant's overall health and quality of health over the last week. Raw scores are calculated by estimating the average of the items that contribute to the scale. Linear transformation is then used to standardize the raw score to a total score range of 0-100. Higher scores for this measure indicate a higher quality of life.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"83.3","lowerLimit":"83.3","upperLimit":"83.3"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Role Functioning","description":"The EORTC Item Library 17 (IL17) role functioning scale measures the degree to which disease or treatment interferes with the participant's work or daily activities. Raw scores are calculated by estimating the average of the items that contribute to the scale. Linear transformation is then used to standardize the raw score to a total score range of 0-100. Higher scores for this measure indicate better outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"91.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"83.3","lowerLimit":"83.3","upperLimit":"83.3"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Lung Cancer Symptoms/How Much Did You Cough","description":"The EORTC IL 85 lung cancer symptoms/how much did you cough measure assesses the severity and frequency of coughing over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath When Rested","description":"The EORTC IL 85 short of breath when rested measure assesses the degree of difficulty breathing while resting over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"2.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath When Walked","description":"The EORTC IL 85 short of breath when walked measure assesses the degree of difficulty breathing while walking over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Short of Breath Climbed Stairs","description":"The EORTC IL 85 short of breath climbed stairs measure assesses the degree of difficulty breathing while climbing stairs over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"86"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","lowerLimit":"2.0","upperLimit":"2.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"79"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Pain in Chest","description":"The EORTC IL 85 pain in chest measure assesses the severity of chest pain over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"3.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Need to Rest","description":"The EORTC IL 132 need to rest measure assesses how often the participant felt the need to rest over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","lowerLimit":"2.0","upperLimit":"2.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Felt Weak","description":"The EORTC IL 132 felt weak measure assesses how often the participant felt weak over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","lowerLimit":"2.0","upperLimit":"2.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Tired","description":"The EORTC IL 132 tired measure assesses how often the participant felt tired over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"2.00","lowerLimit":"2.0","upperLimit":"2.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"78"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"68"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"2.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Change in Participant-reported Outcomes as Assessed by the EORTC: Aches/Pain in Bones","description":"The EORTC IL 188 aches/pain in bones measure assessesthe severity of bone pain over the past week. The single item is scored on a scale of 1-4, with higher scores indicating worse outcomes.","populationDescription":"The analysis population for patient-reported outcomes (PROs) includes all randomized participants. Baseline PRO measurements were taken prior to Cycle 1 Day 1, resulting in few or no data points for that timepoint.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Scores on a scale","timeFrame":"Baseline to week 12","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"88"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 1 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Cycle 2 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"81"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 3 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]},{"title":"Cycle 4 Day 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"},{"groupId":"OG001","value":"1.00","lowerLimit":"1.0","upperLimit":"4.0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Count of participants","timeFrame":"From the start of treatment to 90 days after the final dose of treatment (up to 28 months)","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"90"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"89"}]}]}]},{"type":"SECONDARY","title":"Maximum Serum Concentration (Cmax) of Tobemstomig","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"ug/mL","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"88"}]}],"classes":[{"title":"Tobe + Paclitaxel + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"188","spread":"27.3"}]}]},{"title":"Tobe + Pemetrexed + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"191","spread":"43.1"}]}]}]},{"type":"SECONDARY","title":"Time of Maximum Concentration (Tmax) of Tobemstomig","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Day","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"88"}]}],"classes":[{"title":"Tobe + Paclitaxel + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0649","lowerLimit":"0.0208","upperLimit":"9.13"}]}]},{"title":"Tobe + Pemetrexed + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"0.0646","lowerLimit":"0.0521","upperLimit":"21"}]}]}]},{"type":"SECONDARY","title":"Clearance (CL) of Tobemstomig","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"mL/day","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Tobe + Paclitaxel + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"246","spread":"55.6"}]}]},{"title":"Tobe + Pemetrexed + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"231","spread":"34.5"}]}]}]},{"type":"SECONDARY","title":"Volume of Distribution at Steady State (Vss) of Tobemstomig","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Liters","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Tobe + Paclitaxel + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.65","spread":"40.2"}]}]},{"title":"Tobe + Pemetrexed + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"3.56","spread":"31.6"}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-time Curve (AUC) of Tobemstomig","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"day*ug/mL","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"88"}]}],"classes":[{"title":"Tobe + Paclitaxel + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1470","spread":"31.8"}]}]},{"title":"Tobe + Pemetrexed + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"64"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"1500","spread":"114.2"}]}]}]},{"type":"SECONDARY","title":"Half-life (T1/2) of Tobemstomig","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"Day","timeFrame":"Up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"56"}]}],"classes":[{"title":"Tobe + Paclitaxel + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"14"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"8.45","spread":"196.4"}]}]},{"title":"Tobe + Pemetrexed + Carboplatin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG001","value":"10.4","spread":"83.2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-drug Antibodies (ADAs)","populationDescription":"The pharmacokinetic (PK) population consisted of participants who received IV tobemstomig.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline up to approximately 15 months","groups":[{"id":"OG000","title":"Pembro + Chemotherapy","description":"Participants with squamous or non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment."},{"id":"OG001","title":"Tobe + Chemotherapy","description":"Participants with squamous or NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"77"}]}],"classes":[{"title":"Treatment-Emergent","categories":[{"measurements":[{"groupId":"OG001","value":"42.9"}]}]},{"title":"Treatment-Induced","categories":[{"measurements":[{"groupId":"OG001","value":"42.9"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From the start of treatment to 90 days after the final dose of treatment (up to 28 months)","eventGroups":[{"id":"EG000","title":"Pembro + Chemotherapy (Squamous)","description":"Participants with squamous non small-cell lung cancer (NSCLC) received blinded pembrolizumab (pembro) in combination with paclitaxel and carboplatin on Day 1 every three weeks (Q3W) for four 21-day cycles, followed by blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment.","deathsNumAffected":4,"deathsNumAtRisk":25,"seriousNumAffected":10,"seriousNumAtRisk":25,"otherNumAffected":25,"otherNumAtRisk":25},{"id":"EG001","title":"Pembro + Chemotherapy (Non-squamous)","description":"Participants with non-squamous NSCLC received induction treatment with blinded pembro in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by maintenance therapy with blinded pembro with pemetrexed Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment.","deathsNumAffected":11,"deathsNumAtRisk":65,"seriousNumAffected":26,"seriousNumAtRisk":65,"otherNumAffected":63,"otherNumAtRisk":65},{"id":"EG002","title":"Tobe + Chemotherapy (Squamous)","description":"Participants with SQ NSCLC received blinded tobemstomig in combination with paclitaxel and carboplatin on Day 1 Q3W until disease progression or treatment discontinuation for a maximum of 24 months of treatment.","deathsNumAffected":8,"deathsNumAtRisk":24,"seriousNumAffected":14,"seriousNumAtRisk":24,"otherNumAffected":24,"otherNumAtRisk":24},{"id":"EG003","title":"Tobe + Chemotherapy (Non-squamous)","description":"Participants with NSQ NSCLC received induction treatment with blinded tobemstomig in combination with pemetrexed and carboplatin on Day 1 Q3W for four 21-day cycles, followed by Q3W maintenance therapy with blinded tobemstomig with pemetrexed until disease progression or treatment discontinuation for a maximum of 24 months of treatment.","deathsNumAffected":12,"deathsNumAtRisk":65,"seriousNumAffected":35,"seriousNumAtRisk":65,"otherNumAffected":63,"otherNumAtRisk":65}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":65}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Atrial flutter","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Cardiovascular disorder","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Duodenal ulcer","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Intestinal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Small intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Bacterial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Lymphangitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":6,"numAffected":5,"numAtRisk":65}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pneumonia influenzal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":65}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Myopathy","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Cognitive disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Laryngeal haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":1,"numAtRisk":65}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pulmonary hypertension","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Embolism arterial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":25},{"groupId":"EG001","numEvents":52,"numAffected":40,"numAtRisk":65},{"groupId":"EG002","numEvents":8,"numAffected":6,"numAtRisk":24},{"groupId":"EG003","numEvents":48,"numAffected":35,"numAtRisk":65}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":3,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":8,"numAffected":4,"numAtRisk":65}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":22,"numAffected":16,"numAtRisk":65},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG003","numEvents":32,"numAffected":19,"numAtRisk":65}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":13,"numAffected":8,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":7,"numAffected":6,"numAtRisk":65}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":10,"numAffected":9,"numAtRisk":65}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":65}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":7,"numAffected":7,"numAtRisk":65}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":25},{"groupId":"EG001","numEvents":23,"numAffected":18,"numAtRisk":65},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":25,"numAffected":22,"numAtRisk":65}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":25},{"groupId":"EG001","numEvents":19,"numAffected":16,"numAtRisk":65},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":24},{"groupId":"EG003","numEvents":22,"numAffected":16,"numAtRisk":65}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":4,"numAtRisk":25},{"groupId":"EG001","numEvents":37,"numAffected":24,"numAtRisk":65},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":24},{"groupId":"EG003","numEvents":43,"numAffected":32,"numAtRisk":65}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":15,"numAffected":11,"numAtRisk":65}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":25},{"groupId":"EG001","numEvents":31,"numAffected":20,"numAtRisk":65},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":24},{"groupId":"EG003","numEvents":42,"numAffected":21,"numAtRisk":65}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":4,"numAtRisk":25},{"groupId":"EG001","numEvents":17,"numAffected":14,"numAtRisk":65},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":16,"numAffected":14,"numAtRisk":65}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":65}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":65}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":8,"numAffected":6,"numAtRisk":65}]},{"term":"Conjunctivitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":65}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":6,"numAffected":6,"numAtRisk":65}]},{"term":"Rhinitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":65}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":65}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Infusion related reaction","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":10,"numAffected":6,"numAtRisk":24},{"groupId":"EG003","numEvents":8,"numAffected":5,"numAtRisk":65}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":20,"numAffected":13,"numAtRisk":65}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":4,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":14,"numAffected":10,"numAtRisk":65}]},{"term":"Blood bicarbonate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":65}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":12,"numAffected":9,"numAtRisk":65}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":65}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":9,"numAffected":3,"numAtRisk":65},{"groupId":"EG002","numEvents":7,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":9,"numAffected":3,"numAtRisk":65}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":11,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":7,"numAffected":4,"numAtRisk":65}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":10,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":13,"numAffected":8,"numAtRisk":65}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":1,"numAtRisk":65}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":25},{"groupId":"EG001","numEvents":22,"numAffected":15,"numAtRisk":65},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":18,"numAffected":17,"numAtRisk":65}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":65}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":65},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":65}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":10,"numAffected":7,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":9,"numAffected":6,"numAtRisk":65}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":25},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":65},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":9,"numAffected":8,"numAtRisk":65}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":25},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":65}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":25},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":65},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":14,"numAffected":11,"numAtRisk":65}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":25},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":65},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG003","numEvents":11,"numAffected":9,"numAtRisk":65}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":65}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":65}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":25},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":65},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":65}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":5,"numAtRisk":25},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":65},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":5,"numAffected":5,"numAtRisk":65}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":25},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":65},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":24},{"groupId":"EG003","numEvents":16,"numAffected":12,"numAtRisk":65}]},{"term":"Skin exfoliation","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v27.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":25},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":65},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":65}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"1-800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2024-11-09","uploadDate":"2025-08-27T00:09","filename":"Prot_SAP_000.pdf","size":6243907}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Canada"],"submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2025-09-16","type":"ESTIMATED"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000068437","term":"Pemetrexed"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}